Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study

[1]  Y. Uezono,et al.  Goshajinkigan, a traditional Japanese medicine, prevents oxaliplatin-induced acute peripheral neuropathy by suppressing functional alteration of TRP channels in rat. , 2014, Journal of pharmacological sciences.

[2]  C. Loprinzi,et al.  Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Yi Zhou,et al.  Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Ouyang,et al.  Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis. , 2012, European journal of cancer.

[5]  R. Oishi,et al.  Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents. , 2012, European journal of cancer.

[6]  J. Kigawa,et al.  Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study. , 2012, Experimental and therapeutic medicine.

[7]  K. Kumamoto,et al.  Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer , 2012, International Journal of Clinical Oncology.

[8]  P. Novotny,et al.  Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Watari,et al.  Efficacy of Goshajinkigan for Peripheral Neurotoxicity of Oxaliplatin in Patients with Advanced or Recurrent Colorectal Cancer , 2011, Evidence-based complementary and alternative medicine : eCAM.

[10]  R. Pearson,et al.  Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer , 2010 .

[11]  T. Yano,et al.  Oxaliplatin-induced neuropathy in the rat: Involvement of oxalate in cold hyperalgesia but not mechanical allodynia , 2009, PAIN®.

[12]  J. Sakamoto,et al.  Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study). , 2009, Japanese journal of clinical oncology.

[13]  U. Jaehde,et al.  Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity , 2009, Anti-cancer drugs.

[14]  Tetsuya Imamura,et al.  Gosha‐jinki‐gan reduces transmitter proteins and sensory receptors associated with C fiber activation induced by acetic acid in rat urinary bladder , 2008, Neurourology and urodynamics.

[15]  C. Tournigand,et al.  Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Djulbegovic,et al.  Use of Calcium and Magnesium Salts to Reduce Oxaliplatin-Related Neurotoxicity , 2007 .

[19]  H. Adelsberger,et al.  Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study , 2006, Investigational New Drugs.

[20]  M. Dong.  OPTIMOX1:A Randomized Study of FOLFOX4 or FOLFOX7 with Oxaliplatin in A Stop-and-Go Fashion in Advanced Colorectal Cancer——A GERCOR Study , 2006 .

[21]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[22]  Yuzo Sato,et al.  Effects of Goshajinkigan on insulin resistance in patients with type 2 diabetes. , 2005, Diabetes research and clinical practice.

[23]  Y. Oshida,et al.  Gosha-jinki-gan (a Herbal Complex) Corrects Abnormal Insulin Signaling , 2004, Evidence-based complementary and alternative medicine : eCAM.

[24]  N. Ifrah,et al.  Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions , 2004, Clinical Cancer Research.

[25]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[26]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Sutherland,et al.  Gosha-jinki-gan (herbal medicine) in streptozocin-induced diabetic neuropathy , 1995, Journal of the Neurological Sciences.

[28]  T. Onaya,et al.  The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy. , 1994, Diabetes research and clinical practice.

[29]  S Usuki,et al.  Successful treatment of a senile diabetic woman with cataract with goshajinkigan. , 1991, The American journal of Chinese medicine.